Selective proapoptotic activity of a secreted recombinant antibody/AIF fusion protein in carcinomas overexpressing HER2

Gene Therapy

Volumn 13, Issue 4, 2006, Pages 313-320

  Yu, C J ^a   Jia, L T ^a   Meng, Y L ^a   Zhao, J ^a   Zhang, Y ^a   Qiu, X C ^a   Xu, Y M ^a   Wen, W H ^a   Yao, L B ^a   Fan, D M ^b   Jin, B Q ^a   Chen, S Y ^c   Yang, A G ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Apoptosis inducing factor; HER2 ErbB2 neu; Lymphocytes; Pseudomonas exotoxin

Indexed keywords

APOPTOSIS INDUCING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; LIPOFECTAMINE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; ENDOCYTOSIS; FEASIBILITY STUDY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN SECRETION; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ADP RIBOSE TRANSFERASES; ANTIBODIES; APOPTOSIS; APOPTOSIS INDUCING FACTOR; BACTERIAL TOXINS; CELL LINE; CELL LINE, TUMOR; EXOTOXINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, ERBB-2; HUMANS; JURKAT CELLS; NEOPLASMS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TRANSFECTION; VIRULENCE FACTORS;

ANIMALIA; PSEUDOMONAS EXOTOXIN;

EID: 32444448598     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302672     Document Type: Article

References (45)

1. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
2. Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu IR, Burger RA, DiSaia PJ et al. Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol 2000; 278: 130-136.
3. Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E. HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol 2001; 12: S15-S19.
4. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165-184.
5. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
6. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 2001; 61: 1890-1895.
7. Riese DJ, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998; 20: 41-48.
8. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastases. J Mammary Gland Biol Neoplasia 2001; 6: 393-406.
9. Gancberg D, Di Leo A, Cardoso F, Rouas G, Pedrocchi M, Paesmans M et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13: 1036-1043.
10. Nahta R, Esteva FJ. HER-2-targeted therapy: Lessons learned and future directions. Clin Cancer Res 2003; 9: 5078-5084.
11. Mukai K, Yasutomi Y, Watanabe M, Kenjo A, Aota T, Wang L et al. HER2 peptide-specific CD8(+) T cells are proportionally detectable long after multiple DNA vaccinations. Gene Therapy 2002; 9: 879-888.
12. De Bono JS, Rowinsky EK. The ErbB receptor family: A therapeutic target for cancer. Trends Mol Med 2001; 8: S19-S26.
13. Wester K, Sjostrom A, de la Torre M, Carlsson J, Malmstrom PU. HER-2 - a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 2002; 41: 282-288.
14. Lorenzo HK, Susin SA, Penninger J, Kroemer G. Apoptosis-inducing factor (AIF): A phylogenetically old, caspase-independent effector of cell death. Cell Death Differ 1999; 6: 516-524.
15. Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M et al. Two distinct pathways leading to nuclear apoptosis. J Exp Med 2000; 192: 571-579.
16. Cande C, Cohen I, Daugas E, Ravagnan L, Larochette N, Zamzami N et al. Apoptosis-inducing factor (AIF): A novel caspase-independent death effector released from mitochondria. Biochimie 2002; 84: 215-222.
17. Mate MJ, Ortiz-Lombardia M, Boitel B, Haouz A, Tello D, Susin SA et al. The crystal structure of the mouse apoptosis-inducing factor AIF. Nat Struct Biol 2002; 9: 442-446.
18. Ye H, Cande C, Stephanou NC, Jiang S, Gurbuxani S, Larochette N et al. DNA binding as a structural requirement for the apoptogenic action of AIF. Nat Struct Biol 2002; 9: 680-684.
19. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM et al. Molecular characterization of mitochondrial apoptosisinducing factor. Nature 1999; 397: 441-446.
20. Miramar MD, Costantini P, Ravagnan L, Saraiva LM, Haouzi D, Brothers G et al. NADH-oxidase activity of mitochondrial apoptosis inducing factor (AIF). J Biol Chem 2001; 276: 16391-16398.
21. Daugas E, Nochy D, Ravagnan L, Loeffler M, Susin SA, Zamzami N et al. Apoptosis inducing factor: An ubiquitous mitochondrial oxidoreductase involved in apoptosis regulation. FEBS Lett 2000; 476: 118-123.
22. Loeffler M, Daugas E, Susin SA, Zamzami N, Metivier D, Nieminen AL et al. Dominant cell death induction by extramitochondrially targeted apoptosis inducing factor. FASEB J 2001; 15: 758-767.
23. Dawson VL, Dawson TM. Deadly conversations: Nuclear-mitochondrial cross-talk. J Bioenerg Biomembr 2004; 36: 287-294.
24. Lipton SA, Bossy-Wetzel E. Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Cell 2002; 111: 147-150.
25. Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001; 410: 549-554.
26. Arnoult D, Tatischeff I, Estaquier J, Girard M, Sureau F, Tissier JP et al. On the evolutionary conservation of the cell death pathway: mitochondrial release of an apoptosis inducing factor during Dictyostelium discoideum cell death. Mol Biol Cell 2001; 12: 3016-3030.
27. Braun JS, Novak R, Murray PJ, Eischen CM, Susin SA, Kroemer G et al. Apoptosis-inducing factor mediates microglial and neuronal apoptosis caused by pneumococcus. J Infect Dis 2001; 184: 1300-1309.
28. Cregan SP, Dawson VL, Slack RS. Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004; 23: 2785-2796.
29. Wang X, Yang C, Chai J, Shi Y, Xue D. Mechanisms of AIF-mediated apoptotic DNA degradation in Caenorhabditis elegans. Science 2002; 298: 1587-1592.
30. Wissing S, Ludovico P, Herker E, Buttner S, Engelhardt SM, Decker T et al. An AIF orthologue regulates apoptosis in yeast. J Cell Biol 2004; 166: 969-974.
31. Zhang X, Chen J, Graham SH, Du L, Kochanek PM, Draviam R et al. Intranuclear localization of apoptosis inducing factor (AIF) and large scale DNA fragmentation after traumatic brain injury in rats and in neuronal cultures exposed to peroxynitrite. J Neurochem 2002; 82: 181-191.
32. Lang-Rollin IC, Rideout HJ, Noticewala M, Stefanis L. Mechanisms of caspase-independent neuronal death: Energy depletion and free radical generation. J Neurosci 2003; 23: 11015-11025.
33. Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA 1992; 89: 5867-5871.
34. Chen SY, Yang AG, Chen JD, Kute T, King CR, Collier J et al. Potent antitumor activity of a new class of tumour specific killer cells. Nature 1997; 385: 78-80.
35. Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J Biol Chem 1989; 264: 14256-14261.
36. Siegall CB, Ogata M, Pastan I, FitzGerald DJ. Analysis of sequences in domain II of Pseudomonas exotoxin A which mediate translocation. Biochemistry 1991; 30: 7154-7159.
37. Jia LT, Zhang LH, Yu CJ, Zhao J, Xu YM, Gui JH et al. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res 2003; 63: 3257-3262.
38. Xu YM, Wang LF, Jia LT, Qiu XC, Zhao J, Yu CJ et al. A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors. J Immunol 2004; 173: 61-67.
39. Zhao J, Zhang LH, Jia LT, Zhang L, Xu YM, Wang Z et al. Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells. J Biol Chem 2004; 279: 21343-21348.
40. Yu SW, Wang H, Dawson TM, Dawson VL. Poly (ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. Neurobiol Dis 2003; 14: 303-317.
41. Alano CC, YingW, Swanson RA. Poly (ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition. J Biol Chem 2004; 279: 18895-18902.
42. Cande C, Vahsen N, Kouranti I, Schmitt E, Daugas E, Spahr C et al. AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis. Oncogene 2004; 23: 1514-1521.
43. Hong SJ, Dawson TM, Dawson VL. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci 2004; 25: 259-264.
44. Wang H, Shimoji M, Yu SW, Dawson TM, Dawson VL. Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease. Ann NY Acad Sci 2003; 991: 132-139.
45. Zhang XD, Gillespie SK, Hersey P. Staurosporine induces apoptosis of melanoma by both caspase-dependent and -independent apoptotic pathways. Mol Cancer Ther 2004; 3: 187-197.